Population dynamics and drug resistance mutations in Plasmodium falciparum on the Bijagós Archipelago, Guinea-Bissau

Moss, Sophie; Mańko, Emilia; Vasileva, Hristina; Silva, Eunice Teixeira da; Gonçalves, Adriana; Osborne, Ashley; Phelan, Jody; Rodrigues, Amabélia; Djata, Paulo; D’Alessandro, Umberto; Mabey, David; Krishna, Sanjeev; Last, Anna; Clark, Taane G.; Campino, Susana

doi:10.1038/s41598-023-33176-1

Cited by 3 publications

(1 citation statement)

References 40 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 We are the first group to report activity of OLP in P. falciparum . Since P. falciparum has been gaining resistance to almost all frontline antimalarials 15 , 63 , 64 , 65 as well as artemisinin-based combination treatment (ACT) drug treatment, 15 , 66 OLP could be a possible partner drug for the ACT. Autophagy activated under OLP pressure enables parasite to tolerate and survive the drug pressure.…”

Section: Discussionmentioning

confidence: 99%

Oleuropein activates autophagy to circumvent anti-plasmodial defense

Sharma,

Tandel,

Kumar

et al. 2024

iScience

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Oleuropein activates autophagy to circumvent anti-plasmodial defense

Sharma,

Tandel,

Kumar

et al. 2024

iScience

View full text Add to dashboard Cite

Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial

et al. 2023

Self Cite

View full text Add to dashboard Cite

IntroductionAs malaria declines, innovative tools are required to further reduce transmission and achieve elimination. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) is capable of reducing malaria transmission where coverage of control interventions is already high, though the impact is short-lived. Combining ACT with ivermectin, an oral endectocide shown to reduce vector survival, may increase its impact, while also treating ivermectin-sensitive co-endemic diseases and minimising the potential impact of ACT resistance in this context.Methods and analysisMATAMAL is a cluster-randomised placebo-controlled trial. The trial is being conducted in 24 clusters on the Bijagós Archipelago, Guinea-Bissau, where the peak prevalence ofPlasmodium falciparum(Pf) parasitaemia is approximately 15%. Clusters have been randomly allocated to receive MDA with dihydroartemisinin–piperaquine and either ivermectin or placebo. The primary objective is to determine whether the addition of ivermectin MDA is more effective than dihydroartemisinin–piperaquine MDA alone in reducing the prevalence ofP. falciparumparasitaemia, measured during peak transmission season after 2 years of seasonal MDA. Secondary objectives include assessing prevalence after 1 year of MDA; malaria incidence monitored through active and passive surveillance; age-adjusted prevalence of serological markers indicating exposure toP. falciparumand anopheline mosquitoes; vector parous rates, species composition, population density and sporozoite rates; prevalence of vector pyrethroid resistance; prevalence of artemisinin resistance inP. falciparumusing genomic markers; ivermectin’s impact on co-endemic diseases; coverage estimates; and the safety of combined MDA.Ethics and disseminationThe trial has been approved by the London School of Hygiene and Tropical Medicine’s Ethics Committee (UK) (19156) and the Comite Nacional de Eticas de Saude (Guinea-Bissau) (084/CNES/INASA/2020). Results will be disseminated in peer-reviewed publications and in discussion with the Bissau-Guinean Ministry of Public Health and participating communities.Trial registration numberNCT04844905.

show abstract

Oleuropein mediated autophagy begets antimalarial drug resistance

Sharma,

Chaudhary,

Devi

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

Drug resistance in Plasmodium falciparum presents a formidable challenge to the humanity. And, unavailability of an effective vaccine worsens the situation further. Autophagy is one of the mechanisms employed by parasite to evade drug pressure to survive. Autophagy induced by the P. falciparum in response to the oleuropein pressure may answer many questions related to the parasite survival as well as evolving drug tolerance. The survival/autophagy axis could be an important avenue to explore in order to address certain questions related to the evolution of drug resistance. In addition, humanized mouse model of P. falciparum infection could serve as an important preclinical tool to investigate the oleuropein-induced autophagy, potentially helping to dissect the mechanisms underlying the development of antimalarial drug resistance.

show abstract

Population dynamics and drug resistance mutations in Plasmodium falciparum on the Bijagós Archipelago, Guinea-Bissau

Cited by 3 publications

References 40 publications

Oleuropein activates autophagy to circumvent anti-plasmodial defense

Oleuropein activates autophagy to circumvent anti-plasmodial defense

Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial

Oleuropein mediated autophagy begets antimalarial drug resistance

Contact Info

Product

Resources

About